Introduction to a Symposium on Chronic Myelogenous Leukemia
作者:
ArlinZalmen A.,
期刊:
Cancer Investigation
(Taylor Available online 1988)
卷期:
Volume 6,
issue 6
页码: 735-736
ISSN:0735-7907
年代: 1988
DOI:10.3109/07357908809078040
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractThe discovery of the Philadelphia chromosome as a marker for chronic myelogenous leukemia (CML) in 1960 represented an important scientific breakthrough (1). It established for the first time that a specific chromosomal abnormality was associated with a specific malignancy. Unfortunately, this major event did not translate into direct clinical benefits for patients with this disease. Over the next 20-25 years, our understanding continued to grow while our clinical approach remained essentially unchanged. We know that the Philadelphia chromosome is the result of a translocation (2) and we understand the nature of aberrant and complex translocations (3). A consistent molecular event associated with the Philadelphia chromosome has been characterized (4,5). We understand that Philadelphia-negative CML may have the same molecular basis as Philadelphia-positive CML (6) and the relationship between this disease and Philadelphia-positive acute lymphoblastic leukemia (ALL) has also been clarified (7,8).
点击下载:
PDF (120KB)
返 回